A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (NCT00951665)
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) administered by intravenous (IV) infusion in combination with paclitaxel (Abraxane®; Celgene Corp.) and pertuzumab (Perjeta®; Genentech, Inc.), if applicable, in patients with HER2-positive, locally advanced or metastatic breast cancer.
This trial is sponsored by Genentech, Inc. 
- Condition: Metastatic Breast Cancer
- Phase: I
- Enrollment: 107
- Start: August 2009
- Completion: June 2013
- Last verified: July 2015
Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.